Limited data indicate that breastmilk iron is not increased after intravenous infusion of iron sucrose. Amounts of iron ingested by the infant would be normal and are not expected to cause any adverse effects in breastfed infants. The oral form of the drug, called sucroferric oxyhydroxide and used as a phosphate binder, is not orally absorbed and it is unlikely to reach the breastmilk or adversely affect the breastfed infant. No special precautions are required. For additional information on iron use during breastfeeding, see the monograph on Iron Salts.